Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study

Commentary or Editorial available

Article first published online: 26 Jul 2017
DOI: 10.1111/bjd.15551

Comment on this article



The Psoriasis Stratification to Optimise Relevant Therapy ( PSORT ) consortium has a collective aim to develop a prescribing algorithm to help stratify eligible patients with psoriasis to the most appropriate biological treatment. To facilitate the adoption of a stratified approach, it is necessary to first understand the factors driving the choice of first‐line biological therapy.


To identify and quantify factors that influence the selection of the first‐line biological therapy for people with psoriasis.


Multinomial logistic regression was used to determine the factors that influenced the probability of treatment selection, using data from the British Association of Dermatologists Biologic Interventions Register from January 2012 to December 2015. Sensitivity analyses were performed to assess the robustness of the findings to key assumptions.


The main analysis was based on a dataset comprising 3040 people with psoriasis. The identified factors affecting first‐line biological selection within the available therapies were: presence of psoriatic arthritis; patient weight; employment status; country of registration; and baseline disease severity. Importantly, the analysis showed a general shift in prescribing behaviour over time. These results were robust to sensitivity analysis.


This study offers important insights into the factors influencing current prescribing practice for first‐line biological therapies for people with psoriasis. It provides baseline data to inform the evaluation of future potential changes that may affect prescribing behaviour, such as stratified medicine.

Read moreRead more (PDF)

Share this article




If you want to submit a letter for publication rather than comment on an article please submit through Scholar One:

There are no comments for this article yet.

Recent Tweets


08 Dec 2019

Are you a young dermatologist interested in joining the BJD as an editorial trainee? We have exciting opportunities for international trainees and trainees based in the UK/ Ireland. Find out more on the @HealthySkin4All website:


08 Dec 2019

An unusual case of mycosis fungoides with cerebral involvement, which achieved a durable complete remission after autologous stem-cell transplantation and interferon alfa-2a maintenance therapy. #CTCL #interferon


07 Dec 2019

31M born in Cape Verde presented w/ 3/52 hx of 7cm bosselated & exulcerated plaque w/ rapid growth & bleeding, assoc. w/ wt loss, fatigue & occasional cough. PCR detected Bartonella spp DNA and also tested +ve for HIV. What's your diagnosis? #medderm #BJD


06 Dec 2019

This video gives some insight into novel disease pathomechanisms for the skin fragility disorder #RDEB (Recessive dystrophic epidermolysis bullosa) and identifies potential strategies to improve the disease course of RDEB #SkinFibrosis:


06 Dec 2019

RT The British Association of Dermatologists @HealthySkin4All: New @BrJDermatol research investigated the genetic basis of fibrosis in recessive dystrophic epidermolysis bullosa. This finding could lead to possible future treatment. @CharityDEBRA @Wiley_Health


06 Dec 2019

RT The Dermatology Clinic London @TheDermClinicUK: Does polygenic risk influence associations between sun exposure and #melanoma? A prospective cohort analysis published in @BrJDermatol: #dermatology #skincancer